Evidence map›Paper›PMID 33525065›Full record

ReviewKorean circulation journal2021

Challenges and Limitations of Strategies to Promote Therapeutic Potential of Human Mesenchymal Stem Cells for Cell-Based Cardiac Repair.

Thi Van Anh Bui, Ji Won Hwang, Jung Hoon Lee, Hun Jun Park, Kiwon Ban

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Korean circulation journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Thi Van Anh Bui *Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China.ORCID https://orcid.org/0000-0002-4423-5990
Ji Won Hwang *Department of Biomedicine & Health Sciences, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-9922-364X
Jung Hoon LeeDepartment of Chemistry, City University of Hong Kong, Hong Kong SAR, China.ORCID https://orcid.org/0000-0003-3229-6427
Hun Jun ParkDepartment of Biomedicine & Health Sciences, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-8009-9546
Kiwon BanDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China. kiwonban@cityu.edu.hk.ORCID https://orcid.org/0000-0003-0805-5439
City University of Hong Kong · HKThe Catholic University of Korea Seoul St. Mary's Hospital · KR

Funding

Hong Kong Research Grants Council 21100818National Research Foundation of Korea 2017M3A9B3061954
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) represent a population of adult stem cells residing in many tissues, mainly bone marrow, adipose tissue, and umbilical cord. Due to the safety and availability of standard procedures and protocols for isolation, culturing, and characterization of these cells, MSCs have emerged as one of the most promising sources for cell-based cardiac regenerative therapy. Once transplanted into a damaged heart, MSCs release paracrine factors that nurture the injured area, prevent further adverse cardiac remodeling, and mediate tissue repair along with vasculature. Numerous preclinical studies applying MSCs have provided significant benefits following myocardial infarction. Despite promising results from preclinical studies using animal models, MSCs are not up to the mark for human clinical trials. As a result, various approaches have been considered to promote the therapeutic potency of MSCs, such as genetic engineering, physical treatments, growth factor, and pharmacological agents. Each strategy has targeted one or multi-potentials of MSCs. In this review, we will describe diverse approaches that have been developed to promote the therapeutic potential of MSCs for cardiac regenerative therapy. Particularly, we will discuss major characteristics of individual strategy to enhance therapeutic efficacy of MSCs including scientific principles, advantages, limitations, and improving factors. This article also will briefly introduce recent novel approaches that MSCs enhanced therapeutic potentials of other cells for cardiac repair.

Indexed as

Cell primingHeart failureHuman mesenchymal stem cellsTherapeutic potential

Identifiers

PMID33525065
PMCPMC7853896
OpenAlexW3119359192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.